Non-islet cell tumor hypoglycemia (NICTH
Its mass scales directly with metabolic disease: in individuals with obesity, and especially those with metabolic-associated steatotic liver disease (MASLD, historically called fatty liver), the liver can carry more than a kilogram of excess glycogen, intrahepatic triglyceride (fat), water, and structural protein above its lean baseline
These experiments confirmed that cagrilintide is a potent dual agonist, activating both receptor types, which is crucial for its therapeutic effect on reducing food intake and body weight, as demonstrated in preclinical rat models
Its job is to move fatty acids into mitochondria, where they can be oxidised, or burned, for energy [1]
Real-world evidence in the treatment of ovarian cancer